Market News AIOpen the app

Anavex Life Sciences Corp. says it started a Phase 3 trial for its Rett syndrome drug.

TrialRead the original at sec.gov
Good for AVXL

Anavex said the FDA granted a meeting to discuss adding pediatric patients to its Phase 3 Rett trial. That advances regulatory engagement and the program's development path.

AVXL · Anavex Life Sciences Corp.

AI read · Good for AVXL

The AI's read

Anavex filed an 8-K saying the FDA granted a meeting to discuss adding pediatric patients to its Phase 3 Rett syndrome trial. That regulatory engagement advances the program's development path and supports program value.

Get alerts for AVXL

Follow Anavex Life Sciences Corp. (AVXL) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for AVXL
Free on the App Store and Google Play, or on the web.